Skip to main content

Table 1 Patients’ characteristic

From: Metformin attenuates the production and proliferative effects of prolactin induced by medroxyprogesterone acetate during fertility-sparing treatment for endometrial cancer

 

Median (range)

N (%)

Age (year)                                                                                                                                                      

35 (25–45)

 

Histology Endometrioid carcinoma, grade 1

 

43 (60.6)

EAH

 

28 (39.4)

Treatment MPA + Metformin

 

51 (71.8)

MPA alone

 

20 (28.2)

BMI (kg/m2)

30.4 (15.4–50.3)

 

BMI (kg/m2) ≥ 25

 

47 (66.2)

HOMA-IR

4.0 (0.1–20.7)

 

HOMA-IR ≥ 2.5

 

41 (57.7)

PCOS

 

55 (77.5)

  1. EAH endometrial atypical hyperplasia, MPA medroxyprogesterone acetate, BMI body mass index, HOMA-R homeostasis model assessment of insulin resistance, PCOS polycystic ovarian syndrome